EMVision

Bringing imaging to where stroke occurs will save lives. The ability to distinguish stroke type, size, severity and location at the first point of care, is crucial to successful stroke treatment.

Brisbane brain scanner start-up EMVision to list on ASX with new CEO.

Ground-breaking stroke technology trialled in Australian hospitals.

EMVision’s mission is to be a leading global medical imaging company. The EMVision brain scanner is the product of over a decade of research and development at The University of Queensland.

Anti-bribery & corruption policy Read More »

EMVision’s portable electromagnetic technology aims to reduce time to diagnosis and treatment in medical imaging.

EMVision achieves recruitment milestones for its **emu brain scanner** validation, targeting **ischaemia endpoint** data to strengthen FDA De Novo clearance applications. The company also progresses development of **first-responder brain scanners**, aiming to expand clinical and regulatory value.

Jul 2026Small CapsNews article

EMvision Medical Devices achieves significant clinical trial milestones for its medical device products. The company’s progress places it in focus among investors following positive developments in its research pipeline. No specific details on the milestones or products are provided in the report.

Jul 2026KalkineNews article

EMVision Medical Devices is expanding its pivotal FDA De Novo trial to add acute ischaemia detection for its **emu stroke diagnosis device**, complementing its existing haemorrhage detection endpoint. The trial now covers both critical stroke diagnostic indicators, aiming to enhance early detection capabilities. The device targets faster and more comprehensive stroke diagnosis in clinical settings.

May 2026MedPath TrialNews article

EMVision advances a portable stroke scanner to improve frontline diagnosis. The device aims to reduce delays in critical imaging for stroke patients, where treatment outcomes degrade rapidly. Hospitals currently rely on advanced imaging infrastructure, often limited to specialized facilities.

May 2026The MarketsNews article